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Abstract
Background—Antiretrovirals (ARVs) are recommended for maternal health and to reduce
HIV-1 mother-to-child transmission, but suboptimal adherence can counteract its benefits.
Objectives—To describe antepartum and postpartum adherence to ARV regimens and factors
associated with adherence.
Methods—We assessed adherence rates among subjects enrolled in Pediatric AIDS Clinical
Trials Group Protocol 1025 from August 2002 to July 2005 on tablet formulations with at least
one self-report adherence assessment. Perfectly adherent subjects reported no missed doses 4 days
before their study visit. Generalized estimating equations were used to compare antepartum with
postpartum adherence rates and to identify factors associated with perfect adherence.
Results—Of 519 eligible subjects, 334/445 (75%) reported perfect adherence during pregnancy.
This rate significantly decreased 6, 24, and 48 weeks postpartum [185/284 (65%), 76/118 (64%),
and 42/64 (66%), respectively (P < 0.01)]. Pregnant subjects with perfect adherence had lower
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viral loads. The odds of perfect adherence were significantly higher for women who initiated
ARVs during pregnancy (P < 0.01), did not have AIDS (P = 0.02), never missed prenatal vitamins
(P < 0.01), never used marijuana (P = 0.05), or felt happy all or most of the time (P < 0.01).
Conclusions—Perfect adherence to ARVs was better antepartum, but overall rates were low.
Interventions to improve adherence during pregnancy are needed.
Keywords
pregnancy; adherence; HIV-1 infection; substance use; depression; viral suppression
INTRODUCTION
The morbidity and mortality of HIV-1—infected patients has dramatically decreased in
resource-rich settings with the use of highly active antiretroviral therapy (HAART).1 The
short- and long-term success of HAART is directly related to the degree of adherence to
therapy because adequate therapeutic levels of antiretrovirals (ARVs) are needed to suppress
viral replication and prevent development of resistance.2,3 This is particularly relevant for
protease inhibitor (PI)—based regimens, which require more than 90% adherence to achieve
adequate viral suppression.3-5 Lower ARV adherence rates have been documented in
several populations, including adolescents, active drug users, and patients with mental
illness.6-8 Barriers to adherence include pill burden and limited knowledge of the benefits
of or dosing schedule of ARV therapy.9-12 Overall, average rates of adherence to HAART
among these diverse populations range from 60% to 70%.6-8,10 Thus, increased efforts to
understand and overcome factors related to poor adherence are necessary to optimize health
outcomes.
It is recommended that HIV-1—infected pregnant women receive ARVs during pregnancy
to prevent mother-to-child transmission (MTCT) and/or for their own health.13 Poor
adherence to ARVs during pregnancy can lead to suboptimal viral suppression, development
of viral resistance, a higher risk of MTCT, and MTCT of a resistant HIV-1 strain.2,14-16
Current knowledge of adherence during pregnancy is limited. The objectives of this study
were to estimate and compare rates of self-reported adherence with ARVs among HIV-1—
infected women during pregnancy and postpartum and to identify factors associated with
self-reported adherence.
METHODS
Pediatric AIDS Clinical Trials Group P1025
Pediatric AIDS Clinical Trials Group Protocol 1025 (P1025) is a prospective cohort study of
HIV-1—infected women and their infants. Subjects are enrolled either during pregnancy (as
early as 14 weeks gestation) or postpartum (up to 14 days after delivery) and remain under
follow-up until 48 weeks postpartum.17 Enrollment began in October 2002 and is ongoing.
The objectives of P1025 include assessment of adherence to ARVs during pregnancy and
postpartum.
Study visits occur at 14-20, >20-30, and >30 weeks gestation; at delivery; and at 6, 12, 24,
36, and 48 weeks postpartum. P1025 visits are conducted during routine clinical visits, and
most laboratory measures are abstracted from clinically indicated testing, including flow
cytometry and plasma HIV-1 RNA concentration (viral load). Mode of delivery, pregnancy
outcome, and HIV-1 infection status of the infant are collected. Signs and symptoms are
assessed at each study visit, with abnormalities graded as mild, moderate, severe, or life
threatening. Subjects complete behavioral questionnaires to ascertain substance use patterns
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(alcohol, tobacco, methadone, or illicit drugs such as marijuana, cocaine, heroin, or
amphetamines) that are returned to the data management center in sealed envelopes without
site review. Subjects also complete questionnaires that include quality-of-life issues and a 5-
item version of the Mental Health Inventory to monitor for depression. The 5-item version
of the Mental Health Inventory has been validated as an effective approach to screen
reproductive age women and HIV-1—infected male adults for depression in outpatient
settings.18,19
Information regarding adherence to ARVs is collected by self-report at each study visit
using a questionnaire completed by the subject, which includes current ARV regimen, the
number of doses missed for each ARV of the regimen over the 4 days before the study visit,
and the last time an ARV dose was missed. Additional questions address factors thought to
influence adherence, such as the strength of the subject’s support network, health status,
attitudes regarding taking ARVs, reasons for missing doses, and use of any aids to improve
adherence. The analysis described in this manuscript is limited to assessment of adherence
rates during pregnancy and postpartum, the variables associated with reported perfect
adherence, and the association of adherence with viral load.
Study Population, Outcomes of Interest, and Covariates
Subjects were eligible for inclusion in this analysis if they were enrolled during their first
pregnancy on P1025 by August 1, 2005 (because women participating in the study for a
second time might have different adherence outcomes), had at least one completed self-
report adherence form in the study database during our defined visit windows, and were on a
tablet-based ARV regimen (because the consequences of missing 1 liquid dose may be
different from missing at least one tablet dose). The primary outcome of interest was
adherence to prescribed ARVs during the 4 days before each study visit. Adherence was
classified as perfect if the patient attended the clinic visit, completed the self-report
adherence form, and filled in complete information on all drugs over the 4 days before the
study visit. Conversely, adherence was classified as imperfect if at least one dose of any
ARV had been indicated as being missed or if there was incomplete information on any of
the 4 days. If patients missed the clinic visit or did not submit an adherence assessment, their
adherence outcome was considered to be missing. A second measure of adherence, when the
subject last missed an ARV dose (ranging from never to within the last week), was also
examined. We focused on 4 time points: (1) pregnancy: if a subject completed more than
one adherence assessment during pregnancy, the assessment completed at the study visit
closest to and before delivery was used and if the subject had not yet delivered, the most
recent adherence assessment was used; (2) postpartum, week 6: adherence assessment at a
study visit between 2 and 10 weeks after delivery and closest to week 6; (3) postpartum,
week 24: adherence assessment at a study visit between 20 and 28 weeks after delivery and
closest to week 24; and (4) postpartum, week 48: adherence assessment at a study visit
between 44 and 52 weeks after delivery and closest to week 48.
Covariates collected during the same time window periods and closest to the date of the
adherence assessment were included as independent variables. Substance use during
pregnancy was defined as any reported use of alcohol, methadone, or illicit drugs such as
marijuana, cocaine, heroin, or amphetamines at any time during pregnancy. Substance use
during the postpartum period was defined as any reported use of the same drugs listed above
during pregnancy or up to the adherence assessment date for weeks 6, 24, or 48,
respectively. Information on ARV dosing frequency was taken from the study treatment
record completed by a study nurse. Because the number of pills per dose is not collected, the
most common dosing schedule (based on the experience of 3 of the authors, A.D.B., M.S.,
and R.E.T.) was used for each ARV. Subjects were classified as ARV naive if their first use
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of ARVs was during the index pregnancy. Subjects who had previously used ARVs for their
own health or to decrease MTCT were classified as ARV experienced.
Statistical Methods
Differences in adherence between groups were compared using χ2 test or Fisher exact tests
for categorical data and Wilcoxon rank sum tests for continuous data.20 Relatively few
subjects had adherence data at all 4 time points: subjects who enrolled into P1025 after
delivery had no adherence data collected during pregnancy, some subjects had not
completed all postpartum visits as they were still in follow-up, and, although most subjects
received ARVs during pregnancy, many stopped after delivery if ARV therapy for their own
health was not recommended. Generalized estimating equations (GEEs)21 were used to
model the self-report adherence rates to account for the multiple measurements of each
subject and allow all subjects, regardless of the number of visits, to be included in the
analysis. A binary outcome was used to assess perfect adherence compared with imperfect
adherence using a binomial link, and an ordinal outcome was used to assess when the last
ARV dose had been missed using a multinomial link. Contrasts were set up to formally test
for different adherence rates during pregnancy and across the postpartum visits. To assess
which factors influenced adherence, we fit the GEE models with each factor individually
and then combined them into a multivariate model starting with all factors significant at the
P = 0.10 level and dropping the least significant factor one at a time until the most
parsimonious model was found with all factors significant at the P = 0.05 level. Because
GEEs require strong assumptions regarding missing data (missing completely at random),
analyses were repeated using the subset of subjects with complete data during pregnancy
and at the 6- and 24-week postpartum visits, in the women with adherence assessments
during pregnancy and at least one visit postpartum, and also using nonlinear mixed models,
22 which only require the data to be missing at random.
RESULTS
Study Population
By August 1, 2005, 599 subjects had enrolled into P1025 for the first time, 526 subjects had
at least one self-report adherence form in the database in the time point windows, and 519
were on tablet formulations. These 519 subjects constitute the study population. Of the 73
women on tablet formulations with no adherence forms in the time point windows, 49 had
either enrolled on the study less than 3 months before the data cutoff date or had enrolled
close to delivery and had not yet reached the 6-week follow-up time point, allowing
insufficient time for data entry to have taken place, 6 did have at least one adherence form
but they were completed outside the defined visit windows, and 18 had no adherence forms
submitted with no explanation. The only statistically significant differences between those
included or excluded from the study population (519 vs 80) were in the proportions of
subjects receiving ARVs at enrollment (95% of those included vs 69% of others, P < 0.01)
and in viral loads (28% of those included had detectable viral loads vs 43% of others, P <
0.01). Because subjects had to be receiving ARVs to complete an adherence form and
because women receiving ARVs are more likely to have lower viral loads, these differences
arose because of the inclusion criteria for the analysis.
Baseline characteristics of the study population (at the time of enrollment into P1025) are
shown in Table 1. Of the 519 subjects in the study population, 468 (90%) enrolled before
delivery. Among subjects receiving ARVs at enrollment, the median duration of receipt of
ARVs was 1.3 years. The median CD4 count was 456 cells/mm3, and the median viral load
was,400 copies/mL. Forty-three (8%) subjects reported past or current intravenous drug use
at study entry. During pregnancy, 97/408 (24%) of subjects reported smoking tobacco,
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147/419 (35%) reported using marijuana, 130/416 (31%) reported using alcohol, 64/415
(15%) reported using cocaine, and 85/417 (20%) reported using any illicit drugs (cocaine,
heroin, amphetamines or methamphetamines, or barbiturates) or methadone. The majority of
the study participants received PI-based regimens, whether ascertained cross sectionally at
each adherence assessment (59% as illustrated on Table 1) or longitudinally across up to 4
adherence assessments (63%) (data not shown).
A summary of the number of subjects who were on study, receiving ARVs and with a self-
report adherence form at each time point, is shown in Table 2. Of the 519 women in the
study population, 74 only had adherence information postpartum, 206 only had adherence
information during pregnancy, and 239 had adherence information during pregnancy and at
least one visit after delivery. Among the 360 subjects still receiving ARVs after delivery, an
increasing proportion did not complete the self-report adherence form. Missed study visits
accounted for 37% of the missing forms during the antepartum and postpartum periods, with
the proportion increasing from delivery onward. The remaining subjects attended the study
visit but did not complete the forms. The most common documented reason for not
completing the form was running out of time during the study visit.
Self-report Adherence Rates During Pregnancy and Associations With Viral Load and
CD4+ Count
Among pregnant subjects receiving ARVs and with self-report adherence forms completed
(n = 445), 75% reported perfect adherence during the 4 days before their study visit closest
to and before delivery. The majority (53%) reported that the last time they had missed any
dose was more than 3 months before the study visit. Subjects initiating ARVs during
pregnancy (ARV naive) had lower median plasma HIV-1 RNA (P = 0.01) concentrations
and higher median CD4 counts (P < 0.01) than those who had received ARVs before
pregnancy (ARV experienced, measurements closest to and within 12 weeks before or up to
4 weeks after date of adherence assessment). Overall rates of perfect adherence were higher
among ARV-naive than experienced subjects, although the difference was not statistically
significant (78% vs 72%, P = 0.18). In both groups of subjects, higher rates of perfect
adherence were observed in subjects with lower viral loads, but the differences were only
statistically significant among ARV-experienced subjects (P < 0.01). Specifically, 84% of
subjects with viral loads of ≤50 copies/mL reported perfect adherence compared with 74%
of subjects with viral loads of >50-400 copies/mL and 58% of subjects with >400 copies/mL
(P < 0.01). Differences in perfect adherence according to CD4+ counts did not reach
statistical significance but showed a similar trend: 76% among subjects with CD4+ count
>350 cells/mm3, 74% (201-350 cells/mm3), and 55% (≤200 cells/mm3)(P = 0.08).
Comparison of Self-report Adherence Rates During Pregnancy and Postpartum
Lower proportions of subjects reported perfect adherence postpartum (Table 2); of those
who remained on ARVs postpartum, 185/284 (65%), 76/118 (64%), and 42/64 (66%) had
perfect adherence at 6, 24, and 48 weeks, respectively. Subjects were significantly more
likely to have perfect adherence during pregnancy compared with postpartum [odds ratio =
1.69, 95% confidence interval (CI): 1.25 to 2.27, P < 0.01]. When subjects were asked about
the last time they had missed a dose during pregnancy, 198/440 (45%) reported that they
never missed a dose. Postpartum, this proportion decreased to 109/282 (39%) at 6 weeks,
45/113 (40%) at 24 weeks, and 24/64 (38%) at 48 weeks, showing similar trends as in the
missed dose adherence measure.
We also compared the perfect adherence rates between the 74 women only contributing
adherence assessments postpartum and the 239 women contributing assessments antepartum
and postpartum because the women entering the study later may have been at higher risk due
Bardeguez et al. Page 5
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2009 October 20.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
to inadequate prenatal care. At weeks 6, 24, and 48, they did have lower rates (6%-14%) of
perfect adherence, but the differences were not statistically significant. In addition, the
median time between the first prenatal visit and delivery was longer for the 74 than for the
239 women who had an adherence assessment during pregnancy.
Factors Associated With Perfect Adherence
Results from univariate models relating to covariates collected only during pregnancy are
shown in Table 3. The only factor significantly associated with the odds of perfect
adherence during pregnancy was never missing prenatal vitamins (P < 0.01). Results from
univariate models of correlates of perfect adherence antepartum and postpartum are shown
in Table 4. Perfect adherence rates and the number of subjects in each level of each
covariate are shown during pregnancy and at week 48. These models assume that the effect
of each factor is the same at each time point but are adjusted for the varying adherence rates
at each visit. The frequency of administration was not included as a measure of regimen
complexity as almost all subjects were receiving ARVs twice daily.
The most parsimonious multivariate model of perfect adherence is shown in Table 5. Use of
prenatal vitamins was only collected during pregnancy, so its value was imputed for the
postpartum time points to allow the covariate to be included in the multivariate model.
Subjects who initiated ARVs during the current pregnancy (P < 0.01), those with less
advanced HIV-1 disease (P = 0.02), those who never missed prenatal vitamins (P < 0.01),
those who felt happy all or most of the time (P < 0.01), and those who did not use marijuana
(P = 0.05), had higher odds of perfect adherence. Results for the GEE models were similar
for the subset of women with at least one assessment during pregnancy and at least one after
delivery (n = 239, Table 5), when only subjects with complete data during pregnancy and at
the week 6 and 24 visits were included (n = 71) and when analyzed using nonlinear mixed
models (data not shown).
Factors Associated With Time Since the Last Missed Dose
Univariate and multivariate models were also fit to the answer to the question about when
the subject had last missed an ARV dose. Patients responded on a 6-point scale: never, more
than 3 months ago, 1-3 months ago, 2-4 weeks ago, 1-2 weeks ago, or within the past week.
For analysis, we collapsed the responses into 3 categories: (1) more than 3 months ago, (2)
more than one week ago but less than 3 months ago, or (3) within the last week. Odds ratios
larger than “1” indicate longer times since the last dose was missed relative to the reference
category. Factors significantly associated with a longer time since last missed dose in
univariate models, but which were not statistically significant in the final multivariate
model, included the mother not being infected with HIV-1 perinatally (4.08, 95% CI: 1.72 to
9.69, P = 0.01), disagreeing about friends/family helping take the medications (1.45, 95%
CI: 1.05 to 1.99, P = 0.02), feeling calm and peaceful all or most of the time (1.49, 95% CI:
1.14 to 1.95, P < 0.01), feeling tired none or some of the time (relative to all or most of the
time) (2.05, 95% CI: 1.50 to 2.80, P < 0.01), having enough energy all or most of the time
(1.65, 95% CI: 1.26 to 2.15, P < 0.01), not smoking during the pregnancy or after delivery
(1.53, 95% CI: 1.09 to 2.14, P = 0.02), and being on ARVs less than one year before the
adherence visit (1.54, 95% CI: 1.16 to 2.06, P < 0.01). The final multivariate model (Table
6) included starting ARVs during the current pregnancy, (P < 0.01), never missing prenatal
vitamins (P < 0.01), feeling happy all or most of the time (P = 0.03), no use of marijuana
during pregnancy or postpartum (P = 0.02), and no use of alcohol during pregnancy or
postpartum (P = 0.01) Results for the GEE models were similar for the subset of women
with at least one assessment during pregnancy and at least one after delivery (n = 239, Table
6), when only subjects with complete data during pregnancy and at the week 6 and 24 visits
were included (n = 71) and when analyzed using nonlinear mixed models (data not shown).
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DISCUSSION
Our study showed that, in a cohort of pregnant women primarily receiving PI-based
HAART regimens, only 75% reported perfect adherence during pregnancy, and adherence
rates declined further during the postpartum period. Even among subjects who needed
HAART for their own health according to viral load and CD4 measures, adherence rates
dropped to 65% by 6 weeks postpartum and remained at that level up to 48 weeks
postpartum. Initiation of ARVs during the current pregnancy, less advanced HIV-1 disease,
no use of marijuana, feeling happy all or most of the time, and never missing prenatal
vitamins were significantly associated with perfect self-reported adherence 4 days before the
study visit. The same factors were significantly associated with longer intervals between a
missed dose and the study visit, except for maternal HIV-1 disease stage and alcohol use.
Both ARV-naive and ARV-experienced subjects with lower viral loads closest to the time of
delivery had higher rates of perfect adherence. However, this observation only reached
statistical significance among ARV-experienced subjects.
Our results confirm the correlation between viral load suppression and ARV adherence
previously described by Wilson22 among pregnant women on single drug or combination
ARV regimens and described in other studies of nonpregnant subjects.2,3,23 We also verify,
with a simpler, low-cost approach, the decrease in ARV adherence postpartum as described
by Ickovics et al24 using Medication Events Monitoring Systems. Paterson, Bangsberg, and
others3-5 have shown that, among individuals receiving PI-based regimens, adherence rates
lower than 90% are suboptimal for achieving and maintaining viral suppression. Sixty-three
percent of our study population received a PI-based regimen, and the overall adherence rate
was only 75%, which could lead to the development of ARV resistance among these
reproductive age women. Nonadherent pregnant women might limit their ARV treatment
options in future pregnancies or when treatment is needed for maternal health. Thus, our
observations validate concerns raised by pre-HAART studies and support the imminent need
for effective strategies to enhance adherence in this population.
The rate of illicit drug use within our cohort was higher than anticipated (20%) but
consistent with CDC reports among HIV-1—infected pregnant women.25 Use of alcohol
and marijuana was associated with decreased ARV adherence, confirming previous reports
in nonpregnant subjects.7,9,26 Feeling happy all or most of the time was a significant
predictor of adherence, consistent with depression being a barrier to adherence of ARV
therapy.8,27
Other factors associated with perfect adherence included initiation of ARVs during the
current pregnancy and taking prenatal vitamins as prescribed. Initially described by Wilson,
23 taking vitamins is likely a marker of compliance with all treatment recommendations
including ARVs. ARV-naive patients could be more motivated to be adherent and, in our
cohort, such subjects had lower viral load at entry than ARV-experienced subjects, and thus
their viral suppression might be easier to attain. Alternatively, ARV-experienced subjects
could exhibit signs of treatment fatigue observed among patients with chronic illness, be
depressed, or be challenged by complex HAART regimens which reduce their likelihood of
adherence.28,29 These observations should be confirmed and evaluated in more detail in
future studies.
The complexity of the ARV regimen was not associated with adherence, probably because
there is limited data regarding safety (for the women and the fetus) and pharmacokinetics of
many ARVs during pregnancy, limiting the options when these are used solely for MTCT.
30-34 Most regimens used by the study subjects had similar dosing schedules (twice a day)
and number of pills (each dose consisted of 3-4 pills). Alternatively, this observation could
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imply that, if a patient is committed to taking ARVs, the number of pills or the schedule of
doses does not hinder their adherence. A higher level of education was associated with better
adherence to ARVs in a univariate model, confirming prior reports that low health literacy
hinders understanding of the disease process, treatment options, and ability to follow
treatment instructions.10,12,35 Stone et al10 showed that HIV-1—infected women who
understood the correct dosing of their medications and treatment restrictions had better
adherence.
Our study has certain limitations including solely using patient’s self-report as the
assessment of adherence and relying on self-report of substance abuse. Although, currently,
there is no “gold standard” to measure adherence, this approach may be biased because
subjects want to report better adherence to their caregivers. The generalizability of our
results may be limited because subjects enrolled in P1025 and who were included in our
study population are not necessarily representative of all HIV-1—infected pregnant women
in the United States.17 Our analyses only included subjects who attended study visits, were
receiving ARVs, and who completed the self-report adherence information. Women who
only had adherence assessments postpartum had lower rates of perfect adherence at their
postpartum visits than women with adherence assessments during pregnancy, and it is also
likely that subjects missing study visits or dropping out of this study would be less adherent
to their HIV-1 medications, likely making our reported estimates of rates of perfect
adherence at each time point overly optimistic. This, however, only serves to emphasize the
need for interventions to improve adherence in pregnant HIV-infected women.
Nonetheless, this report summarizes observations from the largest cohort prospectively
monitoring ARV adherence in the HAART era among HIV-1—infected women during and
after pregnancy. In our study, perfect self-reported adherence was associated with viral load,
which validates the utility of this simple, low-cost approach to monitoring adherence. We
also identified characteristics associated with adherence. Thus, subjects without such
characteristics may need additional support with their ARV medications. Future studies
should further investigate tools for depression screening; ascertain the role of ARV-related
toxicities and support networks on adherence; and monitor the consequences of poor
adherence on pregnancy outcomes, rates of MTCT of HIV-1, and the development of ARV
resistance.
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